ABCL vs NEO

ABCL exhibits severe financial distress according to the Piotroski F-Score (1/9), indicating weak operational and financial health. The Altman Z-Score is unavailable, but the company's negative profitability metrics—particularly a -194.88% profit margin and -14.47% ROE—highlight deep operational inefficiencies. Despite a 788.2% YoY revenue growth and strong earnings surprise history (average +30.86% over last 4 quarters), the company remains unprofitable and carries significant valuation risk. The current price of $3.49 trades at a steep 14.08 Price/Sales ratio, far exceeding sector averages, suggesting speculative pricing. Analysts' target price of $9.17 implies strong upside potential, but this is based on unproven profitability and high risk.

NeoGenomics exhibits a stable financial foundation with a Piotroski F-Score of 5/9 and exceptional liquidity (Current Ratio 4.26), though it remains unprofitable with a -14.85% profit margin. While the company has a remarkable track record of beating earnings estimates and shows positive YoY EPS growth, this is offset by a disastrous 5-year price decline of 83.1% and bearish insider activity. The stock appears undervalued relative to analyst targets ($14.81), but the lack of current profitability and negative technical trends suggest a speculative recovery play rather than a value certainty.